PDEXHealthcare · Medical Instruments & Supplies

PDEX Stock Forecast: Pro-Dex, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$63

+0.96% on the day

The 1 Wall Street analysts covering Pro-Dex, Inc. hold a median 12-month price target of $74 — +17.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 12 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap

$202.0M

Ticker Nerd rank

95 / 100

Median analyst target

$74

Analysts covering

Revenue$20.4M+16.6% y/y

Operating income$3.5M

Net income$2.9M

Free cash flow−$476K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−3.5%

+0.4%

YTD

+64.0%

+89.3%

From 52W high

−14.1%

From 52W low

+163.9%

$24

$73

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

PDEX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pro-Dex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026

95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality

Value

Revisions

Momentum

Growth

Size

Issuance

Volatility

Accruals

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PDEX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PDEX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $74Median $74High $74

The green dot is the last close — the median target sits +17.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
11 Sept 2026	Ascendiant Capital	Maintains	Buy	$70 → $74
12 May 2026	Ascendiant Capital	Maintains	Buy	—
12 May 2026	Ascendiant Capital	Maintains	Buy	$56 → $70
27 May 2025	Ascendiant Capital	Maintains	Buy	—
22 Feb 2025	Ascendiant Capital	Maintains	Buy	—
11 Nov 2024	Ascendiant Capital	Maintains	Buy	—
9 Sept 2024	Ascendiant Capital	Maintains	Buy	—
4 Jan 2017	Ascendiant Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDEX appears on the weeks it earns a place.

Performance

PDEX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Pro-Dex, Inc. returned +89.3% against +20.4% for the S&P 500, dividends included.

PDEX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PDEX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

+11.2%

Analysts raising

Analysts cutting

Fundamentals

Pro-Dex, Inc. (PDEX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 15.2×
Price / sales: 2.6×
Price / book: 4.2×
EV / EBITDA: 14.7×

Growth & margins

Revenue growth (YoY): 16.6%
Earnings growth (YoY): 138.7%
Gross margin: 34.8%
Operating margin: 17.3%
Net margin: 17.6%

Returns & dividend

Return on equity: 32.4%
Return on assets: 12.0%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pro-Dex, Inc. (PDEX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Pro-Dex, Inc. has a market value of $202.0M and an enterprise value of $210.8M.
Revenue in the twelve months to 30 June 2026: $77.5M. The latest quarter grew 16.6% year on year.
Net income over the same four quarters: $13.7M, a 17.6% net margin.
Free cash flow in the twelve months to 30 June 2026: $6.8M.
Pro-Dex, Inc. spent $3.4M on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 3.2M.
Trailing P/E: 15.2×; forward P/E: 18.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pro-Dex, Inc. employs 201 people — $386K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Oct 2026

Data provided by Twelve Data

Peers

PDEX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
PDEXPro-Dex, Inc.	$202.0M	95
UTMDUtah Medical Products, Inc.	$236.9M	78
OSUROraSure Technologies, Inc.	$271.0M	88
KRMDKORU Medical Systems, Inc.	$136.4M	94
SMTISanara MedTech, Inc.	$323.0M	91
ZJYLJin Medical International Ltd.	$348.0M	14
EMBCEmbecta Corp.	$354.7M	84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pro-Dex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PDEX news & analysis

5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

Zacks Investment Research · 1 Oct 2026positive

Zacks Investment Research highlighted five medical supply stocks—MCK, CAH, BDX, MMSI and PDEX—as worth watching amid improving industry prospects. PDEX was included on this list of companies with strong potential.

Why it matters — PDEX being named among five medical supply stocks to watch signals that it is gaining attention as a potential beneficiary of improving industry conditions.

SRK Capital 2026 Semi-Annual Portfolio Update

Seeking Alpha · 21 Sept 2026neutral

SRK Fund I, LP posted a 26.80% gain in the first half of the year, outperforming the S&P 500's 10.18% and the Russell 2000's 22.57%. The update highlights ImmuCell's strong first-quarter results and Outdoor Holding Company's shift to a pure-play, asset-light GunBroker.com marketplace after divesting its ammunition business.

Why it matters — A PDEX watcher would care because the update covers portfolio companies and performance trends within the same investing ecosystem that Pro-Dex, Inc. operates in.

Best Momentum Stocks to Buy for September 18th

Zacks Investment Research · 18 Sept 2026positive

Zacks Investment Research reported that Pro-Dex, Inc. (PDEX), along with APH and RELY, was added to its Zacks Rank #1 (Strong Buy) momentum stocks list on September 18th, 2026.

Why it matters — A PDEX watcher would care because inclusion on Zacks' Strong Buy momentum list signals a positive research rating for the stock at that time.

New Strong Buy Stocks for September 18th

Zacks Investment Research · 18 Sept 2026positive

On September 18th, 2026, Pro-Dex, Inc. (PDEX) was added to the Zacks Rank #1 (Strong Buy) List, along with PGY, OPHC, TRV, and HMN, as reported by Zacks Investment Research.

Why it matters — Being added to the Zacks Rank #1 (Strong Buy) List marks a notable recognition of PDEX by the research firm, which PDEX watchers would monitor.

Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results

Accesswire · 3 Sept 2026neutral

Pro-Dex, Inc. announced its financial results for the fiscal 2026 fourth quarter and full year ended June 30, 2026. The announcement was made on September 3, 2026, from the company's Irvine, CA headquarters.

Why it matters — A PDEX watcher would care because the results provide an official update on the company's fourth-quarter and full-year financial performance.

FAQ

Frequently asked questions about PDEX stock

What is the PDEX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Pro-Dex, Inc. have a median 12-month price target of $74, with estimates ranging from $74 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PDEX stock a buy right now?

Of the 1 analysts covering Pro-Dex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pro-Dex, Inc. 95 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PDEX?

As at 12 Oct 2026, Pro-Dex, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will PDEX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +17.3% from the last close, and Ticker Nerd's factor model ranks Pro-Dex, Inc. 95 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PDEX stock forecast for 2030?

No analyst covering Pro-Dex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDEX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $74 over the next 12 months.

How has PDEX stock performed over the past year?

Pro-Dex, Inc. returned +89.3% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pro-Dex, Inc. do?

Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers.

What is the latest news on PDEX?

The most recent item we track (Zacks Investment Research, 1 Oct 2026): "5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve". Zacks Investment Research highlighted five medical supply stocks—MCK, CAH, BDX, MMSI and PDEX—as worth watching amid improving industry prospects. PDEX was included on this list of companies with strong potential.

Company

About Pro-Dex, Inc.

Pro-Dex Inc. is a medical equipment and contract manufacturing company that designs, develops, and manufactures powered surgical instruments for healthcare original equipment manufacturers. Pro-Dex Inc. focuses on autoclavable, battery-powered, and electric surgical drivers and shavers used in orthopedic, thoracic, and craniomaxillofacial procedures. The company also provides engineering, quality, and regulatory consulting services, supporting customers from product design through production. In addition, it produces rotary air motors and related precision components for a range of industrial applications. Pro-Dex Inc. serves medical device distributors, OEMs, and other industrial customers, making it an important supplier in specialized precision manufacturing and surgical technology markets. Headquartered in Irvine, California, Pro-Dex Inc. combines contract manufacturing capabilities with in-house design expertise to deliver customized medical and industrial solutions.

CEO Mr. Richard Lee Van Kirk Jr. · 201 employees · United States · https://www.pro-dex.com